Excelsior Biopharma (6496) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Excelsior Biopharma (6496) has a cash flow conversion efficiency ratio of -0.028x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-22.21 Million ≈ $-699.64K USD) by net assets (NT$804.23 Million ≈ $25.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Excelsior Biopharma to measure how much of total assets are equity-financed.
Excelsior Biopharma - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Excelsior Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Excelsior Biopharma (6496) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Excelsior Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Excelsior Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dancomech Holdings Bhd
KLSE:5276
|
0.019x |
|
Vection Technologies Ltd
AU:VR1
|
0.003x |
|
Novacyt
PA:ALNOV
|
-0.141x |
|
RMB Holdings Ltd
JSE:RMH
|
-0.038x |
|
Daejoo Inc
KQ:003310
|
0.035x |
|
Scynexis Inc
NASDAQ:SCYX
|
0.373x |
|
Aviation Links Ltd
TA:AVIA
|
0.028x |
|
Oricom Inc
KQ:010470
|
0.142x |
Annual Cash Flow Conversion Efficiency for Excelsior Biopharma (2017–2025)
The table below shows the annual cash flow conversion efficiency of Excelsior Biopharma from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Excelsior Biopharma (6496) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$804.23 Million ≈ $25.34 Million |
NT$-138.72 Million ≈ $-4.37 Million |
-0.172x | -71.36% |
| 2024-12-31 | NT$991.45 Million ≈ $31.24 Million |
NT$-99.80 Million ≈ $-3.14 Million |
-0.101x | +17.50% |
| 2023-12-31 | NT$1.10 Billion ≈ $34.80 Million |
NT$-134.75 Million ≈ $-4.25 Million |
-0.122x | -2785.29% |
| 2022-12-31 | NT$1.21 Billion ≈ $38.04 Million |
NT$5.49 Million ≈ $172.84K |
0.005x | -89.99% |
| 2021-12-31 | NT$1.23 Billion ≈ $38.76 Million |
NT$55.82 Million ≈ $1.76 Million |
0.045x | -88.82% |
| 2020-12-31 | NT$1.28 Billion ≈ $40.42 Million |
NT$520.81 Million ≈ $16.41 Million |
0.406x | +400.08% |
| 2019-12-31 | NT$1.25 Billion ≈ $39.53 Million |
NT$-169.74 Million ≈ $-5.35 Million |
-0.135x | -246.36% |
| 2018-12-31 | NT$1.37 Billion ≈ $43.26 Million |
NT$126.92 Million ≈ $4.00 Million |
0.092x | -64.57% |
| 2017-12-31 | NT$1.34 Billion ≈ $42.21 Million |
NT$349.47 Million ≈ $11.01 Million |
0.261x | -- |
About Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more